The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Clovis Oncology, Inc. Common Stock 189464100 1,829,316 101,855 SH   OTR   0 101,855 0
CymaBay Therapeutics, Inc. Common Stock 23257D103 8,536,555 1,084,696 SH   OTR   0 1,084,696 0
Achaogen, Inc. Common Stock 004449104 1,575,817 1,281,152 SH   OTR   0 1,281,152 0
Second Sight Medical Products, Inc. Common Stock 81362J100 3,978,529 4,492,975 SH   OTR   0 4,492,975 0
Ocular Therapeutix, Inc. Common Stock 67576A100 8,817,228 2,215,384 SH   OTR   0 2,215,384 0
Audentes Therapeutics, Inc. Common Stock 05070R104 25,682,392 1,204,615 SH   OTR   0 1,204,615 0
ImmuneDesign Corp. Common Stock 45252L103 2,870,673 2,208,210 SH   OTR   0 2,208,210 0
CRISPR Therapeutics AG Common Stock H17182108 103,105,530 3,608,874 SH   OTR   0 3,608,874 0
OpGen, Inc. Common Stock 68373L109 132,817 102,167 SH   OTR   0 102,167 0
Veracyte, Inc. Common Stock 92337F107 45,492,060 3,616,221 SH   OTR   0 3,616,221 0